Current report filing

Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)

v3.8.0.1
Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)
1 Months Ended 12 Months Ended 77 Months Ended
Sep. 30, 2016
USD ($)
$ / shares
shares
Mar. 31, 2015
USD ($)
Dec. 31, 2016
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Dec. 31, 2017
USD ($)
Aug. 31, 2011
USD ($)
Derivative Liability   $ 63,000 $ 63,000 $ 63,000      
Impairment of Long-Lived Assets to be Disposed of     $ 0 $ 0 $ 0    
Nonsoftware License Arrangement [Member] | SpePharm AG [Member]              
Deferred Revenue, Additions   $ 2,000,000          
Deferred Revenue, Recognition Period   2 years          
Deferred Revenue, Revenue Recognized $ 417,000            
Lymphoseek [Member] | Cardinal Health 414 [Member]              
Sales Revenue, Percent of Sales Made to Entity     99.00% 99.00%      
Series NN Warrants [Member]              
Share-based Compensation Arrangement By Share-based Payment Award Award, Vesting, Threshold Consecutive Trading Days 5            
Minimum [Member]              
Finite-Lived Intangible Asset, Useful Life     5 years        
Maximum [Member]              
Finite-Lived Intangible Asset, Useful Life     15 years        
The 2002 and 2014 Plan [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period     10 years        
The 2002 and 2014 Plan [Member] | Minimum [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period     1 year        
The 2002 and 2014 Plan [Member] | Maximum [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period     4 years        
The 2016 Plan [Member] | Employee Stock Option [Member] | Scenario, Plan [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period 10 years            
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | shares 10,000,000            
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage 100.00%            
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares $ 2.50            
PPCO [Member] | Platinum Loan Agreement [Member] | Fair Value, Inputs, Level 3 [Member]              
Embedded Derivative, Fair Value of Embedded Derivative Liability     $ 153,000 $ 3,000,000      
Former Executive [Member]              
Accounts Payable, Disputed     894,000        
Chief Executive Officer [Member] | Employee Stock Option [Member] | Scenario, Plan [Member]              
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures | shares 5,000,000            
GDS Business [Member              
Disposal Group, Including Discontinued Operation, Consideration             $ 30,300,000
Maximum Royalty Income           $ 20,000,000  
Royalty Revenue, Net     $ 0 759,000 $ 0    
Royalty Revenue, Gross       1,200,000      
Royalty Revenue, Tax Effect Allocated to Discontinued Operations       $ 436,000